1-but-3-enyl-2-methyl-cyclohexene | 22865-35-6

• 分子结构分类: 有机化合物 - 碳氢化合物 - 不饱和烃
• 英文名称: 1-but-3-enyl-2-methyl-cyclohexene
• 英文别名: 1-But-3-enyl-2-methyl-cyclohexen；1-(3-Butenyl)-2-methylcyclohexene；1-but-3-enyl-2-methylcyclohexene
• CAS: 22865-35-6
• 化学式: C₁₁H₁₈
• 分子量: 150.264
• InChiKey: DHSDRGMEYPCRAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 磷酸 作用下， 生成 1-but-3-enyl-2-methyl-cyclohexene
  参考文献：
  名称：

  Budesonide in collagenous colitis: A double-blind placebo-controlled trial with histologic follow-up

  摘要：

  Background & Aims: Collagenous colitis (CC) is a well-described entity causing chronic diarrhea and characteristic histologic findings. Several treatment options have been suggested, but no controlled data are available. We conducted a placebo-controlled trial to show the clinical and histologic effects of budesonide in CC. Methods: Twenty-eight patients were randomly assigned to receive placebo (n = 14) or budesonide 9 mg daily (n = :14) for 8 weeks. Patients were evaluated clinically, and blinded biopsy specimens were analyzed from fixed locations at weeks 0 and 8. Clinical response was defined as a decrease of at least 50% in the disease activity score (number of bowel movements in the last 7 days). At week 8, nonresponders received open-label budesonide for the next 8-week period; responders discontinued treatment and were followed up. Results: Three patients discontinued the study prematurely. Intention-to-treat analysis showed clinical response in 8 of 14 patients in the budesonide group compared with 3 of 14 responders for placebo (P = 0.05) after 8 weeks of blinded therapy, together with improved stool consistency. Histologically, there was no change in the mean thickness of the Collagen band but a significant decrease of the lamina propria infiltrate in the budesonide group (P < 0.001). Conclusions: Budesonide is efficacious in inducing short-term clinical response in CC with significant reduction of the histologic infiltrate in the lamina propria.

  DOI：

  10.1053/gast.2002.30295

文献信息

• Internal reactions of tetraalkylstannanes with carbon-centered electrophiles
  作者：Timothy L. Macdonald、Sankaran Mahalingam、Dale E. O'Dell

  DOI：10.1021/ja00412a049

  日期：1981.11
• MACDONALD, T. L.;MAHALINGAM, SANKARAN;ODELL, D. E., J. AMER. CHEM. SOC., 1981, 103, N 22, 6767-6769
  作者：MACDONALD, T. L.、MAHALINGAM, SANKARAN、ODELL, D. E.

  DOI：——

  日期：——
• Budesonide in collagenous colitis: A double-blind placebo-controlled trial with histologic follow-up
  作者：Filip Baert、Alain Schmit、Geert D'Haens、Franceska Dedeurwaerdere、Edouard Louis、Marc Cabooter、Martine De Vos、Fernand Fontaine、Serge Naegels、Piet Schurmans、Hedwig Stals、Karel Geboes、Paul Rutgeerts

  DOI：10.1053/gast.2002.30295

  日期：2002.1

  Background & Aims: Collagenous colitis (CC) is a well-described entity causing chronic diarrhea and characteristic histologic findings. Several treatment options have been suggested, but no controlled data are available. We conducted a placebo-controlled trial to show the clinical and histologic effects of budesonide in CC. Methods: Twenty-eight patients were randomly assigned to receive placebo (n = 14) or budesonide 9 mg daily (n = :14) for 8 weeks. Patients were evaluated clinically, and blinded biopsy specimens were analyzed from fixed locations at weeks 0 and 8. Clinical response was defined as a decrease of at least 50% in the disease activity score (number of bowel movements in the last 7 days). At week 8, nonresponders received open-label budesonide for the next 8-week period; responders discontinued treatment and were followed up. Results: Three patients discontinued the study prematurely. Intention-to-treat analysis showed clinical response in 8 of 14 patients in the budesonide group compared with 3 of 14 responders for placebo (P = 0.05) after 8 weeks of blinded therapy, together with improved stool consistency. Histologically, there was no change in the mean thickness of the Collagen band but a significant decrease of the lamina propria infiltrate in the budesonide group (P < 0.001). Conclusions: Budesonide is efficacious in inducing short-term clinical response in CC with significant reduction of the histologic infiltrate in the lamina propria.